Page 17 - Read Online

Rajput Cyclical nutritional therapy clinical trial

having regular blood test on her own, initially had a in early androgenic female alopecia. Dermatology 1996;192:28-31.
haemoglobin never above 9.6 gm for past 10 years, 2. Guarrera M, Rebora A. Kenogen in female androgenetic alopecia. A
reported a level of 11 gm in 2 months and 14 gm in longitudinal study. Dermatology 2005;210:18-20.
4 months. Patients had better energy levels, better 3. Trüeb RM. Telogen Effluvium: Is there a need for a new classification?
Skin Appendage Disord 2016;2:39-44.
stamina at work, improvement of small aches and 4. Kligman AM. Pathologic dynamics of human hair loss. I. Telogen
pains, better skin, better nail growth, feeling of effuvium. Arch Dermatol 1961;83:175-98.
wellness, better grasping of studies in college, good 5. Rook A, Dawber R. Chapter 5. Diffuse alopecia: endocrine, metabolic
sleep and waking up fresh, with the vitamin therapy. and chemical influences on the follicular cycle. In: Rook A, Dawber R,
Similar benefits were also reported by Sarris et al. [77] in eds. Diseases of the Hair and Scalp. Oxford, UK: Blackwell Science
their study of multivitamins. Publications;1982:115-45.
6. Headington JT. Telogen effluvium. New concepts and review. Arch
In conclusion, finasteride was introduced for hair 7. Dermatol 1993;129:356-63.
Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med
loss management by serendipity. The benefit from 1999;341:491-7.
finasteride is seen clinically only after 6 to 9 months 8. Liyanage D, Sinclair R. Telogen effluvium. Cosmetics 2016;3:13.
and long term studies have shown that it is effective 9. Chen W, Thiboutot D, Zouboulis CC. Cutaneous androgen
only in 50-60% cases. DHT is not always raised in hair metabolism: basic research and clinical perspectives. J Invest
loss patients. Not high DHT but increased sensitivity Dermatol 2002;119:992-1007.
of the hair follicles is the cause for miniaturization 10. Hoffmann R, Happle R. Current understanding of androgenetic
and hair loss. Instead of long term use of DHT alopecia. Part II: clinical aspects and treatment. Eur J Dermatol
blockers with the fear of side effects, we have studied 2000;10:410-7.
a better option of strengthening the hair roots and 11. Griffin JE, Wilson JD. The metabolic basis of inherited disease.
The resistance syndromes: 5alpha reductase deficiency, testicular
promoting hair growth with nutritional supplements. feminisation and related disorders. New York: McGraw-Hill; 1989.
The prospective controlled clinical trial shows that a p. 1919-44.
low dose cyclical nutritional program planned to avoid 12. Sawaya ME, Price VH. Different levels of 5alpha-reductase type I and
nutrient interactions and improve synergy can be II, aromatase, and androgen receptor in hair follicles of women and
used to achieve consistent hair regrowth in men and men with androgenetic alopecia. J Invest Dermatol 1997;109:296-
women beginning within 2-4 months and continuing to 300.
benefit for 1 year. We can regrow hair safely, without 13. Birch MP, Messenger JF, Messenger AG. Hair density, hair diameter
our patients having to depend on finasteride which and the prevalence of female pattern hair loss. Br J Dermatol
2001;144:297-304.
has been recently recognized to have persistent side 14. Norwood OT. Incidence of female androgenetic alopecia (female
effects. pattern alopecia). Dermatol Surg 2001;27:53-4.
15. Lengg N, Heidecker B, Seifert B, Trüeb RM. Dietary supplement
DECLARATIONS increases anagen hair rate in women with telogen effluvium: results of
a double-blind, placebo-controlled trial. Therapy 2007;4:59-65.
Authors’ contributions 16. Orme S, Cullen DR, Messenger AG. Diffuse female hair loss: are
The author contributed solely to the paper. androgens necessary? Br J Dermatol 1999;141:521-3.
17. Cousen P, Messenger A. Female pattern hair loss in complete
androgen insensitivity syndrome. Br J Dermatol 2010;162:1135-7.
Financial support and sponsorship 18. Urysiak-Czubatka I, Kmieć ML, Broniarczyk-Dyła G. Assessment
None. of the usefulness of dihydrotestosterone in the diagnostics of patients
with androgenetic alopecia. Postepy Dermatol Alergol 2014;31:207-
15.
Conflicts of interest 19. Wolff H, Fischer TW, Blume-Peytavi U. The diagnosis and treatment
There are no conflicts of interest. of hair and scalp diseases. Dtsch Arztebl Int 2016;113:377-86.
20. Trüeb RM. Pharmacologic interventions in aging hair. Clin Interv
Patient consent Aging 2006;1:121-9.
All patients volunteered to give consent and made 21. Goette DK, Odom RB. Alopecia in crash dieters. JAMA
1976;235:2622-3.
a choice to be enrolled in the conventional therapy 22. Fiedler VC, Gray AC. Chapter 10. Diffuse alopecia: telogen hair loss.
group or the nutritional therapy group. All patients also In: Olsen EA, ed. Disorders of Hair Growth: Diagnosis and Treatment.
agreed to complete the study for a period of one year. 2nd ed. New York, NY: McGraw-Hill Publishing; 2003:303-20.
23. Sinclair RD, Dawber RP. Androgenetic alopecia in men and women.
Ethics approval Clin Dermatol 2001;19:167-78.
Not applicable. 24. Rajput R. Understanding hair loss due to air pollution and the approach
to management. Hair Ther Transplant 2015;5:133.
25. Rajput RS. Benefit from vitamin therapy in smoker’s hair. Hair Ther
REFERENCES Transplant 2016;6:141.
26. Sinclair R. Diffuse hair loss. Int J Dermatol 1999;38 Suppl 1:8-18.
1. Guarrera M, Rebora A. Anagen hairs may fail to replace telogen hairs 27. Lee WS, Lee HJ. Characteristics of androgenetic alopecia in asian.
Plastic and Aesthetic Research ¦ Volume 4 ¦ September 30, 2017 171